Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Pierre Feugier

31PUBLICATIONS
350CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical biotechnology diagnostics (incl. biosensors)Haematological tumoursEpigenetics (incl. genome methylation and epigenomics)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

Sort by Publication Date:
|Jul 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

|May 14, 2026
Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).

|Mar 31, 2026
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Nicolas Gower, Pierre Feugier, Jason R Westin

|Nov 03, 2025
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Mouhamad Khouja, Elisa Genuardi, Simone Ferrero

|Sep 13, 2025
Intensive Treatment in Adult Burkitt Lymphoma with Lymphome Malin B (LMB) Regimen: Excellent Outcomes Despite Substantial Toxicity and Supportive Care Demands.

Ivan Dlouhy, Diana Viegas, Inês Coelho

|Jan 22, 2025
Detection of clinically relevant variants in the <i>TP53</i> gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.

Sarka Pavlova, Jitka Malcikova, Lenka Radova

Pageof 6

Frequent Collaborators

9 joint publications

Oliver A Cornely

9 joint publications

Livio Pagano

9 joint publications

Jon Salmanton-García

9 joint publications

Francesco Marchesi

8 joint publications

Raquel Nunes-Rodrigues

8 joint publications

Monia Marchetti

8 joint publications

Matteo Bonnani

7 joint publications

Martin Hoenigl

7 joint publications

Alberto López-García

7 joint publications

Caroline Besson

Frequent Collaborators

9 joint publications

Oliver A Cornely

9 joint publications

Livio Pagano

9 joint publications

Jon Salmanton-García

9 joint publications

Francesco Marchesi